Fig. 4
From: KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors
Efficacy of metastasis status. A Subgroup analysis of ORR by liver metastasis status; B subgroup analysis of ORR by brain metastasis status; C subgroup analysis of 12-month OS by brain metastasis status